AB-PINACA

AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012.^[2]

AB-PINACA

Legal status
Legal status	BR: Class F2 (Prohibited psychotropics)[1] CA: Schedule II DE: Anlage II (Authorized trade only, not prescriptible) UK: Class B US: Schedule I
Identifiers
IUPAC name N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide
CAS Number	1445752-09-9 Y
PubChem CID	71301472
ChemSpider	28537615
UNII	6J3KC3S2PA
KEGG	C22704
CompTox Dashboard (EPA)	DTXSID00904034
Chemical and physical data
Formula	C18H26N4O2
Molar mass	330.432 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCCn1c2ccccc2c(n1)C(=O)N[C@@H](C(C)C)C(=O)N
InChI InChI=1S/C18H26N4O2/c1-4-5-8-11-22-14-10-7-6-9-13(14)16(21-22)18(24)20-15(12(2)3)17(19)23/h6-7,9-10,12,15H,4-5,8,11H2,1-3H3,(H2,19,23)(H,20,24)/t15-/m0/s1 Key:GIMHPAQOAAZSHS-HNNXBMFYSA-N

It was originally developed by Pfizer in 2009 as an analgesic medication.^[3][4]

AB-PINACA acts as a potent agonist for the CB₁ receptor (K_i = 2.87 nM, EC₅₀ = 1.2 nM) and CB₂ receptor (K_i = 0.88 nM, EC₅₀ = 2.5 nM) and fully substitutes for Δ⁹-THC in rat discrimination studies, while being 1.5x more potent.^[5][6]

There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.^[7][8]

Legal status

Germany

AB-PINACA is an Anlage II controlled substance in Germany as of November 2014.^[9]

Singapore

It is listed in the Fifth Schedule of the Misuse of Drugs Act and so is illegal in Singapore, as of May 2015.^[10]

United States

It is a Schedule I controlled substance in the United States.^[11]

China

It is a controlled substance in China as of October 2015.^[12]

France

It is a controlled substance in France as of March 2017.^[13]

See also

• 5F-AB-PINACA
• 5F-ADB
• 5F-AMB
• 5F-APINACA
• 5F-CUMYL-PINACA
• AB-CHFUPYCA
• AB-FUBINACA
• AB-PICA
• ADB-CHMINACA
• ADB-FUBINACA
• ADB-PINACA
• ADBICA
• APICA
• APINACA
• MDMB-CHMICA
• PX-3

References

1. Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
2. Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y (2012). "New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products". Forensic Toxicology. 31: 93–100. doi:10.1007/s11419-012-0171-4. S2CID 25242453.
3. "AB-PINACA". Cayman Chemical. Retrieved 25 June 2015.
4. WO 2009106980A, Buchler IP, Hayes MJ, Hegde SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK, "Indazole derivatives", published 3 September 2009, assigned to Pfizer Inc.
5. Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, et al. (September 2015). "Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA". ACS Chemical Neuroscience. 6 (9): 1546–1559. doi:10.1021/acschemneuro.5b00112. PMID 26134475.
6. Wiley JL, Marusich JA, Lefever TW, Antonazzo KR, Wallgren MT, Cortes RA, et al. (September 2015). "AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol-Like Effects in Mice". The Journal of Pharmacology and Experimental Therapeutics. 354 (3): 328–339. doi:10.1124/jpet.115.225326. PMC 4538877. PMID 26105953.
7. Trecki J, Gerona RR, Schwartz MD (July 2015). "Synthetic Cannabinoid-Related Illnesses and Deaths". The New England Journal of Medicine. 373 (2): 103–107. doi:10.1056/NEJMp1505328. PMID 26154784.
8. Thornton SL, Akpunonu P, Glauner K, Hoehn KS, Gerona R (September 2015). "Unintentional Pediatric Exposure to a Synthetic Cannabinoid (AB-PINACA) Resulting in Coma and Intubation". Annals of Emergency Medicine. 66 (3): 343–344. doi:10.1016/j.annemergmed.2015.05.021. PMID 26304261.
9. "Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel)" [Law on the Traffic in Narcotic Substances (Narcotics Act - BtMG) Annex II (to Section 1 Paragraph 1) (marketable but not prescription narcotics)]. Retrieved 22 June 2015.
10. "Misuse of Drugs Act". Central Narcotics Bureau (CNB). 30 April 2015. Archived from the original on 15 July 2015. Retrieved 24 July 2015.
11. "Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into schedule I. Final order" (PDF). Drug Enforcement Administration, U.S. Department of Justice. 30 January 2015. Retrieved 9 July 2015.
12. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" [Notice on Issuing the Measures for the Listing and Control of Non-Medicinal Narcotic Drugs and Psychotropic Substances] (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
13. "Arrêté du 31 mars 2017 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants" [Order of March 31, 2017 amending the order of February 22, 1990 establishing the list of substances classified as narcotics] (in French). Legifrance. 6 April 2017. Retrieved 6 April 2017.